Since the TRPC4/C5 antagonists inhibit both TRPC4 or TRPC5 homomeric channels and TRPC1/C4 and TRPC1/C5 heteromeric channels, these data support the general idea that targeting TRPC1/C4/C5 channels can be beneficial to stroke therapy including post ischemic protection. This evidence concerns the gene TRPC4 and stroke disorder.